ID   HMGB1_HUMAN             Reviewed;         215 AA.
AC   P09429; A5D8W9; Q14321; Q5T7C3; Q6IBE1;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-JUN-2021, entry version 227.
DE   RecName: Full=High mobility group protein B1;
DE   AltName: Full=High mobility group protein 1;
DE            Short=HMG-1;
GN   Name=HMGB1; Synonyms=HMG1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2922262; DOI=10.1093/nar/17.3.1197;
RA   Wen L., Huang J.K., Johnson B.H., Reeck G.R.;
RT   "A human placental cDNA clone that encodes nonhistone chromosomal protein
RT   HMG-1.";
RL   Nucleic Acids Res. 17:1197-1214(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8661151; DOI=10.1006/geno.1996.0369;
RA   Ferrari S., Finelli P., Rocchi M., Bianchi M.E.;
RT   "The active gene that encodes human high mobility group 1 protein (HMG1)
RT   contains introns and maps to chromosome 13.";
RL   Genomics 35:367-371(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ARG-11; GLU-149 AND GLY-190.
RX   PubMed=9036861;
RX   DOI=10.1002/(sici)1097-0215(19970220)74:1<1::aid-ijc1>3.0.co;2-6;
RA   Xiang Y.-Y., Wang D.-Y., Tanaka M., Suzuki M., Kiyokawa E., Igarashi H.,
RA   Niato Y., Shen Q., Sugimura H.;
RT   "Expression of high-mobility group-1 mRNA in human gastrointestinal
RT   adenocarcinoma and corresponding non-cancerous mucosa.";
RL   Int. J. Cancer 74:1-6(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=17610420; DOI=10.1111/j.1399-0039.2007.00854.x;
RA   Kornblit B., Munthe-Fog L., Petersen S., Madsen H., Vindeloev L.,
RA   Garred P.;
RT   "The genetic variation of the human HMGB1 gene.";
RL   Tissue Antigens 70:151-156(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   He F.T., Yang Z.H., Ji Q., Li R., Peng J., Jiang Y., Zhong X.;
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Small intestine;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLN-156.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUL-2007) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, Cervix, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   PROTEIN SEQUENCE OF 58-65 AND 113-127.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=9150946; DOI=10.1002/elps.1150180342;
RA   Rasmussen R.K., Ji H., Eddes J.S., Moritz R.L., Reid G.E., Simpson R.J.,
RA   Dorow D.S.;
RT   "Two-dimensional electrophoretic analysis of human breast carcinoma
RT   proteins: mapping of proteins that bind to the SH3 domain of mixed lineage
RT   kinase MLK2.";
RL   Electrophoresis 18:588-598(1997).
RN   [15]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=11154118;
RA   Rouhiainen A., Imai S., Rauvala H., Parkkinen J.;
RT   "Occurrence of amphoterin (HMG1) as an endogenous protein of human
RT   platelets that is exported to the cell surface upon platelet activation.";
RL   Thromb. Haemost. 84:1087-1094(2000).
RN   [16]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12231511; DOI=10.1093/embo-reports/kvf198;
RA   Gardella S., Andrei C., Ferrera D., Lotti L.V., Torrisi M.R., Bianchi M.E.,
RA   Rubartelli A.;
RT   "The nuclear protein HMGB1 is secreted by monocytes via a non-classical,
RT   vesicle-mediated secretory pathway.";
RL   EMBO Rep. 3:995-1001(2002).
RN   [17]
RP   SUBCELLULAR LOCATION.
RX   PubMed=14532127; DOI=10.1093/emboj/cdg516;
RA   Bonaldi T., Talamo F., Scaffidi P., Ferrera D., Porto A., Bachi A.,
RA   Rubartelli A., Agresti A., Bianchi M.E.;
RT   "Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it
RT   towards secretion.";
RL   EMBO J. 22:5551-5560(2003).
RN   [18]
RP   FUNCTION, AND DOMAIN.
RX   PubMed=12765338; DOI=10.1007/bf03402105;
RA   Li J., Kokkola R., Tabibzadeh S., Yang R., Ochani M., Qiang X.,
RA   Harris H.E., Czura C.J., Wang H., Ulloa L., Wang H., Warren H.S.,
RA   Moldawer L.L., Fink M.P., Andersson U., Tracey K.J., Yang H.;
RT   "Structural basis for the proinflammatory cytokine activity of high
RT   mobility group box 1.";
RL   Mol. Med. 9:37-45(2003).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH MSH2.
RX   PubMed=15014079; DOI=10.1074/jbc.m401931200;
RA   Yuan F., Gu L., Guo S., Wang C., Li G.M.;
RT   "Evidence for involvement of HMGB1 protein in human DNA mismatch repair.";
RL   J. Biol. Chem. 279:20935-20940(2004).
RN   [20]
RP   INVOLVEMENT IN INFLAMMATORY DISEASES.
RX   PubMed=14695889; DOI=10.1073/pnas.2434651100;
RA   Yang H., Ochani M., Li J., Qiang X., Tanovic M., Harris H.E., Susarla S.M.,
RA   Ulloa L., Wang H., DiRaimo R., Czura C.J., Wang H., Roth J., Warren H.S.,
RA   Fink M.P., Fenton M.J., Andersson U., Tracey K.J.;
RT   "Reversing established sepsis with antagonists of endogenous high-mobility
RT   group box 1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:296-301(2004).
RN   [21]
RP   FUNCTION.
RX   PubMed=16143102; DOI=10.1016/j.cell.2005.06.027;
RA   Zhang Y., Yuan F., Presnell S.R., Tian K., Gao Y., Tomkinson A.E., Gu L.,
RA   Li G.-M.;
RT   "Reconstitution of 5'-directed human mismatch repair in a purified
RT   system.";
RL   Cell 122:693-705(2005).
RN   [22]
RP   INTERACTION WITH THBD.
RX   PubMed=15841214; DOI=10.1172/jci200522782;
RA   Abeyama K., Stern D.M., Ito Y., Kawahara K., Yoshimoto Y., Tanaka M.,
RA   Uchimura T., Ida N., Yamazaki Y., Yamada S., Yamamoto Y., Yamamoto H.,
RA   Iino S., Taniguchi N., Maruyama I.;
RT   "The N-terminal domain of thrombomodulin sequesters high-mobility group-B1
RT   protein, a novel antiinflammatory mechanism.";
RL   J. Clin. Invest. 115:1267-1274(2005).
RN   [23]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15944249; DOI=10.4049/jimmunol.174.12.7506;
RA   Dumitriu I.E., Baruah P., Valentinis B., Voll R.E., Herrmann M.,
RA   Nawroth P.P., Arnold B., Bianchi M.E., Manfredi A.A., Rovere-Querini P.;
RT   "Release of high mobility group box 1 by dendritic cells controls T cell
RT   activation via the receptor for advanced glycation end products.";
RL   J. Immunol. 174:7506-7515(2005).
RN   [24]
RP   FUNCTION.
RX   PubMed=15607795; DOI=10.1016/j.molimm.2004.07.023;
RA   DeMarco R.A., Fink M.P., Lotze M.T.;
RT   "Monocytes promote natural killer cell interferon gamma production in
RT   response to the endogenous danger signal HMGB1.";
RL   Mol. Immunol. 42:433-444(2005).
RN   [25]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16855214; DOI=10.1152/ajpcell.00616.2005;
RA   Bell C.W., Jiang W., Reich C.F., Pisetsky D.S.;
RT   "The extracellular release of HMGB1 during apoptotic cell death.";
RL   Am. J. Physiol. 291:C1318-C1325(2006).
RN   [26]
RP   DISULFIDE BRIDGE, AND REDOX FORMS.
RX   PubMed=16962095; DOI=10.1016/j.yexcr.2006.07.020;
RA   Hoppe G., Talcott K.E., Bhattacharya S.K., Crabb J.W., Sears J.E.;
RT   "Molecular basis for the redox control of nuclear transport of the
RT   structural chromatin protein Hmgb1.";
RL   Exp. Cell Res. 312:3526-3538(2006).
RN   [27]
RP   PHOSPHORYLATION, MUTAGENESIS OF SER-35; SER-39; SER-42; SER-46; SER-53 AND
RP   SER-181, SUBCELLULAR LOCATION, AND INTERACTION WITH KPNA1.
RX   PubMed=17114460; DOI=10.4049/jimmunol.177.11.7889;
RA   Youn J.H., Shin J.S.;
RT   "Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that
RT   redirects it toward secretion.";
RL   J. Immunol. 177:7889-7897(2006).
RN   [28]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-106.
RX   PubMed=18631454; DOI=10.1016/j.immuni.2008.05.013;
RA   Kazama H., Ricci J.E., Herndon J.M., Hoppe G., Green D.R., Ferguson T.A.;
RT   "Induction of immunological tolerance by apoptotic cells requires caspase-
RT   dependent oxidation of high-mobility group box-1 protein.";
RL   Immunity 29:21-32(2008).
RN   [29]
RP   FUNCTION.
RX   PubMed=17803946; DOI=10.1016/j.molcel.2007.06.029;
RA   Prasad R., Liu Y., Deterding L.J., Poltoratsky V.P., Kedar P.S.,
RA   Horton J.K., Kanno S., Asagoshi K., Hou E.W., Khodyreva S.N., Lavrik O.I.,
RA   Tomer K.B., Yasui A., Wilson S.H.;
RT   "HMGB1 is a cofactor in mammalian base excision repair.";
RL   Mol. Cell 27:829-841(2007).
RN   [30]
RP   FUNCTION, TISSUE SPECIFICITY, AND INVOLVEMENT IN AUTOIMMUNE DISEASES.
RX   PubMed=19064698; DOI=10.1084/jem.20081165;
RA   Urbonaviciute V., Furnrohr B.G., Meister S., Munoz L., Heyder P.,
RA   De Marchis F., Bianchi M.E., Kirschning C., Wagner H., Manfredi A.A.,
RA   Kalden J.R., Schett G., Rovere-Querini P., Herrmann M., Voll R.E.;
RT   "Induction of inflammatory and immune responses by HMGB1-nucleosome
RT   complexes: implications for the pathogenesis of SLE.";
RL   J. Exp. Med. 205:3007-3018(2008).
RN   [31]
RP   FUNCTION, AND INTERACTION WITH IL1B.
RX   PubMed=18250463; DOI=10.4049/jimmunol.180.4.2531;
RA   Sha Y., Zmijewski J., Xu Z., Abraham E.;
RT   "HMGB1 develops enhanced proinflammatory activity by binding to
RT   cytokines.";
RL   J. Immunol. 180:2531-2537(2008).
RN   [32]
RP   FUNCTION.
RX   PubMed=18354232; DOI=10.4049/jimmunol.180.7.5067;
RA   Youn J.H., Oh Y.J., Kim E.S., Choi J.E., Shin J.S.;
RT   "High mobility group box 1 protein binding to lipopolysaccharide
RT   facilitates transfer of lipopolysaccharide to CD14 and enhances
RT   lipopolysaccharide-mediated TNF-alpha production in human monocytes.";
RL   J. Immunol. 180:5067-5074(2008).
RN   [33]
RP   INTERACTION WITH HNF1A.
RX   PubMed=18160415; DOI=10.1093/nar/gkm1131;
RA   Yu M., Wang J., Li W., Yuan Y.Z., Li C.Y., Qian X.H., Xu W.X., Zhan Y.Q.,
RA   Yang X.M.;
RT   "Proteomic screen defines the hepatocyte nuclear factor 1alpha-binding
RT   partners and identifies HMGB1 as a new cofactor of HNF1alpha.";
RL   Nucleic Acids Res. 36:1209-1219(2008).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-35 AND SER-100, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [35]
RP   REDOX FORMS, AND SUBCELLULAR LOCATION.
RX   PubMed=19811284; DOI=10.1080/08916930902831803;
RA   Urbonaviciute V., Meister S., Furnrohr B.G., Frey B., Guckel E., Schett G.,
RA   Herrmann M., Voll R.E.;
RT   "Oxidation of the alarmin high-mobility group box 1 protein (HMGB1) during
RT   apoptosis.";
RL   Autoimmunity 42:305-307(2009).
RN   [36]
RP   FUNCTION, AND INTERACTION WITH XPA AND XPC.
RX   PubMed=19446504; DOI=10.1016/j.dnarep.2009.04.001;
RA   Lange S.S., Reddy M.C., Vasquez K.M.;
RT   "Human HMGB1 directly facilitates interactions between nucleotide excision
RT   repair proteins on triplex-directed psoralen interstrand crosslinks.";
RL   DNA Repair 8:865-872(2009).
RN   [37]
RP   REVIEW ON FUNCTION RELATED TO DNA REPAIR.
RX   PubMed=19360789; DOI=10.1002/mc.20544;
RA   Lange S.S., Vasquez K.M.;
RT   "HMGB1: the jack-of-all-trades protein is a master DNA repair mechanic.";
RL   Mol. Carcinog. 48:571-580(2009).
RN   [38]
RP   FUNCTION, INTERACTION WITH CD24, AND LIGAND FOR CD24:SIGLEC10 RECEPTOR
RP   COMPLEX.
RX   PubMed=19264983; DOI=10.1126/science.1168988;
RA   Chen G.Y., Tang J., Zheng P., Liu Y.;
RT   "CD24 and Siglec-10 selectively repress tissue damage-induced immune
RT   responses.";
RL   Science 323:1722-1725(2009).
RN   [39]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-30, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [40]
RP   REVIEW ON FUNCTION RELATED TO DNA-BINDING.
RX   PubMed=20123072; DOI=10.1016/j.bbagrm.2009.09.008;
RA   Stros M.;
RT   "HMGB proteins: interactions with DNA and chromatin.";
RL   Biochim. Biophys. Acta 1799:101-113(2010).
RN   [41]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH BECN1.
RX   PubMed=20819940; DOI=10.1083/jcb.200911078;
RA   Tang D., Kang R., Livesey K.M., Cheh C.W., Farkas A., Loughran P.,
RA   Hoppe G., Bianchi M.E., Tracey K.J., Zeh H.J. III, Lotze M.T.;
RT   "Endogenous HMGB1 regulates autophagy.";
RL   J. Cell Biol. 190:881-892(2010).
RN   [42]
RP   FUNCTION, LIGAND FOR TLR4:LY96 RECEPTOR COMPLEX, AND DOMAIN.
RX   PubMed=20547845; DOI=10.1073/pnas.1003893107;
RA   Yang H., Hreggvidsdottir H.S., Palmblad K., Wang H., Ochani M., Li J.,
RA   Lu B., Chavan S., Rosas-Ballina M., Al-Abed Y., Akira S., Bierhaus A.,
RA   Erlandsson-Harris H., Andersson U., Tracey K.J.;
RT   "A critical cysteine is required for HMGB1 binding to Toll-like receptor 4
RT   and activation of macrophage cytokine release.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:11942-11947(2010).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-35, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [44]
RP   FUNCTION.
RX   PubMed=21395369; DOI=10.1089/ars.2010.3666;
RA   Tang D., Kang R., Livesey K.M., Zeh H.J., Lotze M.T.;
RT   "High mobility group box 1 (HMGB1) activates an autophagic response to
RT   oxidative stress.";
RL   Antioxid. Redox Signal. 15:2185-2195(2011).
RN   [45]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [46]
RP   LPS-BINDING.
RX   PubMed=21660935; DOI=10.1002/eji.201141391;
RA   Youn J.H., Kwak M.S., Wu J., Kim E.S., Ji Y., Min H.J., Yoo J.H.,
RA   Choi J.E., Cho H.S., Shin J.S.;
RT   "Identification of lipopolysaccharide-binding peptide regions within HMGB1
RT   and their effects on subclinical endotoxemia in a mouse model.";
RL   Eur. J. Immunol. 41:2753-2762(2011).
RN   [47]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-35, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [48]
RP   FUNCTION.
RX   PubMed=22473704; DOI=10.1093/intimm/dxs051;
RA   Wild C.A., Bergmann C., Fritz G., Schuler P., Hoffmann T.K., Lotfi R.,
RA   Westendorf A., Brandau S., Lang S.;
RT   "HMGB1 conveys immunosuppressive characteristics on regulatory and
RT   conventional T cells.";
RL   Int. Immunol. 24:485-494(2012).
RN   [49]
RP   FUNCTION, AND INTERACTION WITH CXCL12.
RX   PubMed=22370717; DOI=10.1084/jem.20111739;
RA   Schiraldi M., Raucci A., Munoz L.M., Livoti E., Celona B., Venereau E.,
RA   Apuzzo T., De Marchis F., Pedotti M., Bachi A., Thelen M., Varani L.,
RA   Mellado M., Proudfoot A., Bianchi M.E., Uguccioni M.;
RT   "HMGB1 promotes recruitment of inflammatory cells to damaged tissues by
RT   forming a complex with CXCL12 and signaling via CXCR4.";
RL   J. Exp. Med. 209:551-563(2012).
RN   [50]
RP   REDOX FORMS, AND SUBCELLULAR LOCATION.
RX   PubMed=22869893; DOI=10.1084/jem.20120189;
RA   Venereau E., Casalgrandi M., Schiraldi M., Antoine D.J., Cattaneo A.,
RA   De Marchis F., Liu J., Antonelli A., Preti A., Raeli L., Shams S.S.,
RA   Yang H., Varani L., Andersson U., Tracey K.J., Bachi A., Uguccioni M.,
RA   Bianchi M.E.;
RT   "Mutually exclusive redox forms of HMGB1 promote cell recruitment or
RT   proinflammatory cytokine release.";
RL   J. Exp. Med. 209:1519-1528(2012).
RN   [51]
RP   ACETYLATION.
RX   PubMed=22801494; DOI=10.1038/nature11290;
RA   Lu B., Nakamura T., Inouye K., Li J., Tang Y., Lundbaeck P.,
RA   Valdes-Ferrer S.I., Olofsson P.S., Kalb T., Roth J., Zou Y.,
RA   Erlandsson-Harris H., Yang H., Ting J.P., Wang H., Andersson U.,
RA   Antoine D.J., Chavan S.S., Hotamisligil G.S., Tracey K.J.;
RT   "Novel role of PKR in inflammasome activation and HMGB1 release.";
RL   Nature 488:670-674(2012).
RN   [52]
RP   INVOLVEMENT IN CANCER THERAPY.
RX   PubMed=23040637; DOI=10.1016/j.ejca.2012.09.016;
RA   Luo Y., Chihara Y., Fujimoto K., Sasahira T., Kuwada M., Fujiwara R.,
RA   Fujii K., Ohmori H., Kuniyasu H.;
RT   "High mobility group box 1 released from necrotic cells enhances regrowth
RT   and metastasis of cancer cells that have survived chemotherapy.";
RL   Eur. J. Cancer 49:741-751(2013).
RN   [53]
RP   REVIEW ON FUNCTION RELATED TO ADAPTIVE IMUNNITY.
RX   PubMed=23519706; DOI=10.3389/fimmu.2013.00068;
RA   Li G., Liang X., Lotze M.T.;
RT   "HMGB1: The central cytokine for all lymphoid cells.";
RL   Front. Immunol. 4:68-68(2013).
RN   [54]
RP   FUNCTION, AND INTERACTION WITH HTT.
RX   PubMed=23303669; DOI=10.4049/jimmunol.1202472;
RA   Min H.J., Ko E.A., Wu J., Kim E.S., Kwon M.K., Kwak M.S., Choi J.E.,
RA   Lee J.E., Shin J.S.;
RT   "Chaperone-like activity of high-mobility group box 1 protein and its role
RT   in reducing the formation of polyglutamine aggregates.";
RL   J. Immunol. 190:1797-1806(2013).
RN   [55]
RP   REVIEW ON FUNCTION RELATED TO INFLAMMATION.
RX   PubMed=23446148; DOI=10.1189/jlb.1212662;
RA   Yang H., Antoine D.J., Andersson U., Tracey K.J.;
RT   "The many faces of HMGB1: molecular structure-functional activity in
RT   inflammation, apoptosis, and chemotaxis.";
RL   J. Leukoc. Biol. 93:865-873(2013).
RN   [56]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-35, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [57]
RP   REVIEW.
RX   PubMed=23994764; DOI=10.1016/j.semcancer.2013.08.002;
RA   Li G., Tang D., Lotze M.T.;
RT   "Menage a Trois in stress: DAMPs, redox and autophagy.";
RL   Semin. Cancer Biol. 23:380-390(2013).
RN   [58]
RP   FUNCTION.
RX   PubMed=24971542; DOI=10.1016/j.bbrc.2014.06.074;
RA   Liu L., Yang M., Kang R., Dai Y., Yu Y., Gao F., Wang H., Sun X., Li X.,
RA   Li J., Wang H., Cao L., Tang D.;
RT   "HMGB1-DNA complex-induced autophagy limits AIM2 inflammasome activation
RT   through RAGE.";
RL   Biochem. Biophys. Res. Commun. 450:851-856(2014).
RN   [59]
RP   FUNCTION, MUTAGENESIS OF ASP-67, INTERACTION WITH AGER, DOMAIN, AND
RP   PROTEOLYTIC CLEAVAGE.
RX   PubMed=24474694; DOI=10.1074/jbc.m113.541474;
RA   LeBlanc P.M., Doggett T.A., Choi J., Hancock M.A., Durocher Y., Frank F.,
RA   Nagar B., Ferguson T.A., Saleh M.;
RT   "An immunogenic peptide in the A-box of HMGB1 protein reverses apoptosis-
RT   induced tolerance through RAGE receptor.";
RL   J. Biol. Chem. 289:7777-7786(2014).
RN   [60]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [61]
RP   NOMENCLATURE OF REDOX FORMS.
RX   PubMed=24531895; DOI=10.2119/molmed.2014.00022;
RA   Antoine D.J., Harris H.E., Andersson U., Tracey K.J., Bianchi M.E.;
RT   "A systematic nomenclature for the redox states of high mobility group box
RT   (HMGB) proteins.";
RL   Mol. Med. 20:135-137(2014).
RN   [62]
RP   REVIEW ON INVOLVEMENT IN DISEASES AND THERAPEUTIC TARGET.
RX   PubMed=24220159; DOI=10.1016/j.pharmthera.2013.11.001;
RA   Musumeci D., Roviello G.N., Montesarchio D.;
RT   "An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-
RT   related pathologies.";
RL   Pharmacol. Ther. 141:347-357(2014).
RN   [63]
RP   FUNCTION.
RX   PubMed=25549101; DOI=10.1371/journal.pone.0115809;
RA   Lee L.C., Chen C.M., Wang P.R., Su M.T., Lee-Chen G.J., Chang C.Y.;
RT   "Role of high mobility group box 1 (HMGB1) in SCA17 pathogenesis.";
RL   PLoS ONE 9:E115809-E115809(2014).
RN   [64]
RP   REVIEW ON FUNCTION RELATED TO INNATE IMMUNITY.
RX   PubMed=25048472; DOI=10.3349/ymj.2014.55.5.1165;
RA   Lee S.A., Kwak M.S., Kim S., Shin J.S.;
RT   "The role of high mobility group box 1 in innate immunity.";
RL   Yonsei Med. J. 55:1165-1176(2014).
RN   [65]
RP   INVOLVEMENT AUTOIMMUNE DISEASES.
RX   PubMed=26078984; DOI=10.1155/2015/946748;
RA   Lu M., Yu S., Xu W., Gao B., Xiong S.;
RT   "HMGB1 promotes systemic lupus erythematosus by enhancing macrophage
RT   inflammatory response.";
RL   J. Immunol. Res. 2015:946748-946748(2015).
RN   [66]
RP   FUNCTION.
RX   PubMed=25660311; DOI=10.1159/000369972;
RA   Kwak M.S., Lim M., Lee Y.J., Lee H.S., Kim Y.H., Youn J.H., Choi J.E.,
RA   Shin J.S.;
RT   "HMGB1 binds to lipoteichoic acid and enhances TNF-alpha and IL-6
RT   production through HMGB1-mediated transfer of lipoteichoic acid to CD14 and
RT   TLR2.";
RL   J. Innate Immun. 7:405-416(2015).
RN   [67]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [68]
RP   FUNCTION, INTERACTION WITH ADENOVIRUS PROTEIN PVII (MICROBIAL INFECTION),
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=27362237; DOI=10.1038/nature18317;
RA   Avgousti D.C., Herrmann C., Kulej K., Pancholi N.J., Sekulic N.,
RA   Petrescu J., Molden R.C., Blumenthal D., Paris A.J., Reyes E.D.,
RA   Ostapchuk P., Hearing P., Seeholzer S.H., Worthen G.S., Black B.E.,
RA   Garcia B.A., Weitzman M.D.;
RT   "A core viral protein binds host nucleosomes to sequester immune danger
RT   signals.";
RL   Nature 535:173-177(2016).
RN   [69]
RP   ADP-RIBOSYLATION AT SER-181.
RX   PubMed=28190768; DOI=10.1016/j.molcel.2017.01.003;
RA   Bonfiglio J.J., Fontana P., Zhang Q., Colby T., Gibbs-Seymour I.,
RA   Atanassov I., Bartlett E., Zaja R., Ahel I., Matic I.;
RT   "Serine ADP-ribosylation depends on HPF1.";
RL   Mol. Cell 0:0-0(2017).
RN   [70]
RP   SUBCELLULAR LOCATION, AND TRANSGLUTAMINATION AT LYS-28; LYS-43; LYS-44;
RP   LYS-68; LYS-177; LYS-180; LYS-182; LYS-183 AND LYS-184.
RX   PubMed=29618516; DOI=10.1074/jbc.ra117.001078;
RA   Willis W.L., Wang L., Wada T.T., Gardner M., Abdouni O., Hampton J.,
RA   Valiente G., Young N., Ardoin S., Agarwal S., Freitas M.A., Wu L.C.,
RA   Jarjour W.N.;
RT   "The proinflammatory protein HMGB1 is a substrate of transglutaminase-2 and
RT   forms high-molecular weight complexes with autoantigens.";
RL   J. Biol. Chem. 293:8394-8409(2018).
RN   [71]
RP   FUNCTION, FUNCTION (MICROBIAL INFECTION), SUBCELLULAR LOCATION, AND
RP   INDUCTION BY SARS-COV2 (MICROBIAL INFECTION).
RX   DOI=10.1016/j.cell.2020.10.028;
RA   Wei J., Alfajaro M.M., DeWeirdt P.C., Hanna R.E., Lu-Culligan W.J.,
RA   Cai W.L., Strine M.S., Zhang S.-M., Graziano V.R., Schmitz C.O., Chen J.S.,
RA   Mankowski M.C., Filler R.B., Ravindra N.G., Gasque V., de Miguel F.J.,
RA   Patil A., Chen H., Oguntuyo K.Y., Abriola L., Surovtseva Y.V.,
RA   Orchard R.C., Lee B., Lindenbach B.D., Politi K., van Dijk D., Kadoch C.,
RA   Simon M.D., Yan Q., Doench J.G., Wilen C.B.;
RT   "Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2
RT   infection.";
RL   Cell 0:0-0(2020).
RN   [72]
RP   STRUCTURE BY NMR OF 1-166.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the tandem HMG box domain from human high mobility
RT   group protein B1.";
RL   Submitted (FEB-2008) to the PDB data bank.
RN   [73]
RP   STRUCTURE BY NMR OF 2-84 IN COMPLEX WITH TP53, FUNCTION, AND DOMAIN.
RX   PubMed=23063560; DOI=10.1016/j.str.2012.09.004;
RA   Rowell J.P., Simpson K.L., Stott K., Watson M., Thomas J.O.;
RT   "HMGB1-facilitated p53 DNA binding occurs via HMG-Box/p53 transactivation
RT   domain interaction, regulated by the acidic tail.";
RL   Structure 20:2014-2024(2012).
RN   [74]
RP   STRUCTURE BY NMR OF 1-84.
RX   PubMed=24427810; DOI=10.1016/j.bbrc.2013.10.085;
RA   Wang J., Tochio N., Takeuchi A., Uewaki J., Kobayashi N., Tate S.;
RT   "Redox-sensitive structural change in the A-domain of HMGB1 and its
RT   implication for the binding to cisplatin modified DNA.";
RL   Biochem. Biophys. Res. Commun. 441:701-706(2013).
CC   -!- FUNCTION: Multifunctional redox sensitive protein with various roles in
CC       different cellular compartments. In the nucleus is one of the major
CC       chromatin-associated non-histone proteins and acts as a DNA chaperone
CC       involved in replication, transcription, chromatin remodeling, V(D)J
CC       recombination, DNA repair and genome stability (Ref.71). Proposed to be
CC       an universal biosensor for nucleic acids. Promotes host inflammatory
CC       response to sterile and infectious signals and is involved in the
CC       coordination and integration of innate and adaptive immune responses.
CC       In the cytoplasm functions as sensor and/or chaperone for immunogenic
CC       nucleic acids implicating the activation of TLR9-mediated immune
CC       responses, and mediates autophagy. Acts as danger associated molecular
CC       pattern (DAMP) molecule that amplifies immune responses during tissue
CC       injury (PubMed:27362237). Released to the extracellular environment can
CC       bind DNA, nucleosomes, IL-1 beta, CXCL12, AGER isoform 2/sRAGE,
CC       lipopolysaccharide (LPS) and lipoteichoic acid (LTA), and activates
CC       cells through engagement of multiple surface receptors. In the
CC       extracellular compartment fully reduced HMGB1 (released by necrosis)
CC       acts as a chemokine, disulfide HMGB1 (actively secreted) as a cytokine,
CC       and sulfonyl HMGB1 (released from apoptotic cells) promotes
CC       immunological tolerance (PubMed:23519706, PubMed:23446148,
CC       PubMed:23994764, PubMed:25048472). Has proangiogdenic activity (By
CC       similarity). May be involved in platelet activation (By similarity).
CC       Binds to phosphatidylserine and phosphatidylethanolamide (By
CC       similarity). Bound to RAGE mediates signaling for neuronal outgrowth
CC       (By similarity). May play a role in accumulation of expanded
CC       polyglutamine (polyQ) proteins such as huntingtin (HTT) or TBP
CC       (PubMed:23303669, PubMed:25549101). {ECO:0000250|UniProtKB:P10103,
CC       ECO:0000250|UniProtKB:P12682, ECO:0000250|UniProtKB:P63158,
CC       ECO:0000250|UniProtKB:P63159, ECO:0000269|PubMed:23303669,
CC       ECO:0000269|PubMed:25549101, ECO:0000269|PubMed:27362237,
CC       ECO:0000269|Ref.71, ECO:0000305|PubMed:23446148,
CC       ECO:0000305|PubMed:23519706, ECO:0000305|PubMed:23994764,
CC       ECO:0000305|PubMed:25048472}.
CC   -!- FUNCTION: Nuclear functions are attributed to fully reduced HGMB1.
CC       Associates with chromatin and binds DNA with a preference to non-
CC       canonical DNA structures such as single-stranded DNA, DNA-containing
CC       cruciforms or bent structures, supercoiled DNA and ZDNA. Can bent DNA
CC       and enhance DNA flexibility by looping thus providing a mechanism to
CC       promote activities on various gene promoters by enhancing transcription
CC       factor binding and/or bringing distant regulatory sequences into close
CC       proximity (PubMed:20123072). May have an enhancing role in nucleotide
CC       excision repair (NER) (By similarity). However, effects in NER using in
CC       vitro systems have been reported conflictingly (PubMed:19446504,
CC       PubMed:19360789). May be involved in mismatch repair (MMR) and base
CC       excision repair (BER) pathways (PubMed:15014079, PubMed:16143102,
CC       PubMed:17803946). May be involved in double strand break repair such as
CC       non-homologous end joining (NHEJ) (By similarity). Involved in V(D)J
CC       recombination by acting as a cofactor of the RAG complex: acts by
CC       stimulating cleavage and RAG protein binding at the 23 bp spacer of
CC       conserved recombination signal sequences (RSS) (By similarity). In
CC       vitro can displace histone H1 from highly bent DNA (By similarity). Can
CC       restructure the canonical nucleosome leading to relaxation of
CC       structural constraints for transcription factor-binding (By
CC       similarity). Enhances binding of sterol regulatory element-binding
CC       proteins (SREBPs) such as SREBF1 to their cognate DNA sequences and
CC       increases their transcriptional activities (By similarity). Facilitates
CC       binding of TP53 to DNA (PubMed:23063560). Proposed to be involved in
CC       mitochondrial quality control and autophagy in a transcription-
CC       dependent fashion implicating HSPB1; however, this function has been
CC       questioned (By similarity). Can modulate the activity of the telomerase
CC       complex and may be involved in telomere maintenance (By similarity).
CC       {ECO:0000250|UniProtKB:P10103, ECO:0000250|UniProtKB:P63158,
CC       ECO:0000250|UniProtKB:P63159, ECO:0000269|PubMed:15014079,
CC       ECO:0000269|PubMed:16143102, ECO:0000269|PubMed:17803946,
CC       ECO:0000269|PubMed:19446504, ECO:0000269|PubMed:23063560,
CC       ECO:0000305|PubMed:19360789, ECO:0000305|PubMed:20123072}.
CC   -!- FUNCTION: In the cytoplasm proposed to dissociate the BECN1:BCL2
CC       complex via competitive interaction with BECN1 leading to autophagy
CC       activation (PubMed:20819940). Involved in oxidative stress-mediated
CC       autophagy (PubMed:21395369). Can protect BECN1 and ATG5 from calpain-
CC       mediated cleavage and thus proposed to control their proautophagic and
CC       proapoptotic functions and to regulate the extent and severity of
CC       inflammation-associated cellular injury (By similarity). In myeloid
CC       cells has a protective role against endotoxemia and bacterial infection
CC       by promoting autophagy (By similarity). Involved in endosomal
CC       translocation and activation of TLR9 in response to CpG-DNA in
CC       macrophages (By similarity). {ECO:0000250|UniProtKB:P63158,
CC       ECO:0000269|PubMed:20819940, ECO:0000269|PubMed:21395369}.
CC   -!- FUNCTION: In the extracellular compartment (following either active
CC       secretion or passive release) involved in regulation of the
CC       inflammatory response. Fully reduced HGMB1 (which subsequently gets
CC       oxidized after release) in association with CXCL12 mediates the
CC       recruitment of inflammatory cells during the initial phase of tissue
CC       injury; the CXCL12:HMGB1 complex triggers CXCR4 homodimerization
CC       (PubMed:22370717). Induces the migration of monocyte-derived immature
CC       dendritic cells and seems to regulate adhesive and migratory functions
CC       of neutrophils implicating AGER/RAGE and ITGAM (By similarity). Can
CC       bind to various types of DNA and RNA including microbial unmethylated
CC       CpG-DNA to enhance the innate immune response to nucleic acids.
CC       Proposed to act in promiscuous DNA/RNA sensing which cooperates with
CC       subsequent discriminative sensing by specific pattern recognition
CC       receptors (By similarity). Promotes extracellular DNA-induced AIM2
CC       inflammasome activation implicating AGER/RAGE (PubMed:24971542).
CC       Disulfide HMGB1 binds to transmembrane receptors, such as AGER/RAGE,
CC       TLR2, TLR4 and probably TREM1, thus activating their signal
CC       transduction pathways. Mediates the release of cytokines/chemokines
CC       such as TNF, IL-1, IL-6, IL-8, CCL2, CCL3, CCL4 and CXCL10
CC       (PubMed:12765338, PubMed:18354232, PubMed:19264983, PubMed:20547845,
CC       PubMed:24474694). Promotes secretion of interferon-gamma by macrophage-
CC       stimulated natural killer (NK) cells in concert with other cytokines
CC       like IL-2 or IL-12 (PubMed:15607795). TLR4 is proposed to be the
CC       primary receptor promoting macrophage activation and signaling through
CC       TLR4 seems to implicate LY96/MD-2 (PubMed:20547845). In bacterial
CC       LPS- or LTA-mediated inflammatory responses binds to the endotoxins and
CC       transfers them to CD14 for signaling to the respective TLR4:LY96 and
CC       TLR2 complexes (PubMed:18354232, PubMed:21660935, PubMed:25660311).
CC       Contributes to tumor proliferation by association with ACER/RAGE (By
CC       similarity). Can bind to IL1-beta and signals through the IL1R1:IL1RAP
CC       receptor complex (PubMed:18250463). Binding to class A CpG activates
CC       cytokine production in plasmacytoid dendritic cells implicating TLR9,
CC       MYD88 and AGER/RAGE and can activate autoreactive B cells. Via HMGB1-
CC       containing chromatin immune complexes may also promote B cell responses
CC       to endogenous TLR9 ligands through a B-cell receptor (BCR)-dependent
CC       and ACER/RAGE-independent mechanism (By similarity). Inhibits
CC       phagocytosis of apoptotic cells by macrophages; the function is
CC       dependent on poly-ADP-ribosylation and involves binding to
CC       phosphatidylserine on the cell surface of apoptotic cells (By
CC       similarity). In adaptive immunity may be involved in enhancing immunity
CC       through activation of effector T cells and suppression of regulatory T
CC       (TReg) cells (PubMed:15944249, PubMed:22473704). In contrast, without
CC       implicating effector or regulatory T-cells, required for tumor
CC       infiltration and activation of T-cells expressing the lymphotoxin
CC       LTA:LTB heterotrimer thus promoting tumor malignant progression (By
CC       similarity). Also reported to limit proliferation of T-cells (By
CC       similarity). Released HMGB1:nucleosome complexes formed during
CC       apoptosis can signal through TLR2 to induce cytokine production
CC       (PubMed:19064698). Involved in induction of immunological tolerance by
CC       apoptotic cells; its pro-inflammatory activities when released by
CC       apoptotic cells are neutralized by reactive oxygen species (ROS)-
CC       dependent oxidation specifically on Cys-106 (PubMed:18631454). During
CC       macrophage activation by activated lymphocyte-derived self apoptotic
CC       DNA (ALD-DNA) promotes recruitment of ALD-DNA to endosomes (By
CC       similarity). {ECO:0000250|UniProtKB:P10103,
CC       ECO:0000250|UniProtKB:P63158, ECO:0000250|UniProtKB:P63159,
CC       ECO:0000269|PubMed:12765338, ECO:0000269|PubMed:15607795,
CC       ECO:0000269|PubMed:15944249, ECO:0000269|PubMed:18250463,
CC       ECO:0000269|PubMed:18354232, ECO:0000269|PubMed:18631454,
CC       ECO:0000269|PubMed:19064698, ECO:0000269|PubMed:19264983,
CC       ECO:0000269|PubMed:20547845, ECO:0000269|PubMed:21660935,
CC       ECO:0000269|PubMed:22370717, ECO:0000269|PubMed:22473704,
CC       ECO:0000269|PubMed:24474694, ECO:0000269|PubMed:24971542,
CC       ECO:0000269|PubMed:25660311, ECO:0000269|Ref.8}.
CC   -!- FUNCTION: (Microbial infection) Critical for entry of human
CC       coronaviruses SARS-CoV and SARS-CoV-2, as well as human coronavirus
CC       NL63/HCoV-NL63. Regulates the expression of the pro-viral genes ACE2
CC       and CTSL through chromatin modulation. {ECO:0000269|Ref.71}.
CC   -!- SUBUNIT: Interacts (fully reduced HMGB1) with CXCL12; probably in a 1:2
CC       ratio involving two molecules of CXCL12, each interacting with one HMG
CC       box of HMGB1; inhibited by glycyrrhizin (PubMed:22370717). Associates
CC       with the TLR4:LY96 receptor complex (PubMed:20547845). Component of the
CC       RAG complex composed of core components RAG1 and RAG2, and associated
CC       component HMGB1 or HMGB2 (By similarity). Interacts (in cytoplasm upon
CC       starvation) with BECN1; inhibits the interaction of BECN1 and BCL2
CC       leading to promotion of autophagy (PubMed:20819940). Interacts with
CC       KPNA1; involved in nuclear import (PubMed:17114460). Interacts with
CC       SREBF1, TLR2, TLR4, TLR9, PTPRZ1, APEX1, FEN1, POLB, TERT (By
CC       similarity). Interacts with IL1B, AGER, MSH2, XPA, XPC, HNF1A, TP53
CC       (PubMed:15014079, PubMed:18250463, PubMed:18160415, PubMed:19446504,
CC       PubMed:24474694, PubMed:23063560). Interacts with CD24; the probable
CC       CD24:SIGLEC10 complex is proposed to inhibit HGMB1-mediated tissue
CC       damage immune response (PubMed:19264983). Interacts with THBD; prevents
CC       HGMB1 interaction with ACER/RAGE and inhibits HGMB1 proinflammatory
CC       activity (PubMed:15841214). Interacts with HAVCR2; impairs HMGB1
CC       binding to B-DNA and likely HMGB1-mediated innate immune response (By
CC       similarity). Interacts with XPO1; mediating nuclear export (By
CC       similarity). Interacts with HTT (wild-type and mutant HTT with expanded
CC       polyglutamine repeat) (PubMed:23303669). {ECO:0000250|UniProtKB:P63158,
CC       ECO:0000250|UniProtKB:P63159, ECO:0000269|PubMed:15014079,
CC       ECO:0000269|PubMed:15841214, ECO:0000269|PubMed:17114460,
CC       ECO:0000269|PubMed:17803946, ECO:0000269|PubMed:18160415,
CC       ECO:0000269|PubMed:18250463, ECO:0000269|PubMed:19264983,
CC       ECO:0000269|PubMed:19446504, ECO:0000269|PubMed:20547845,
CC       ECO:0000269|PubMed:20819940, ECO:0000269|PubMed:22370717,
CC       ECO:0000269|PubMed:23063560, ECO:0000269|PubMed:23303669,
CC       ECO:0000269|PubMed:24474694}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with adenovirus protein pVII;
CC       this interaction immobilizes HMGB1 on chromatin, thus preventing its
CC       release from cell and subsequent inflammation activation.
CC       {ECO:0000269|PubMed:27362237}.
CC   -!- INTERACTION:
CC       P09429; Q15109: AGER; NbExp=3; IntAct=EBI-389432, EBI-1646426;
CC       P09429; Q6RW13: AGTRAP; NbExp=3; IntAct=EBI-389432, EBI-741181;
CC       P09429; P05067: APP; NbExp=3; IntAct=EBI-389432, EBI-77613;
CC       P09429; Q14457: BECN1; NbExp=2; IntAct=EBI-389432, EBI-949378;
CC       P09429; O95273: CCNDBP1; NbExp=3; IntAct=EBI-389432, EBI-748961;
CC       P09429; Q00839: HNRNPU; NbExp=3; IntAct=EBI-389432, EBI-351126;
CC       P09429; P42858: HTT; NbExp=13; IntAct=EBI-389432, EBI-466029;
CC       P09429; P08729: KRT7; NbExp=6; IntAct=EBI-389432, EBI-297833;
CC       P09429; P43246: MSH2; NbExp=2; IntAct=EBI-389432, EBI-355888;
CC       P09429; P09874: PARP1; NbExp=2; IntAct=EBI-389432, EBI-355676;
CC       P09429; Q96T23: RSF1; NbExp=3; IntAct=EBI-389432, EBI-926768;
CC       P09429; P84103: SRSF3; NbExp=3; IntAct=EBI-389432, EBI-372557;
CC       P09429; P04637: TP53; NbExp=9; IntAct=EBI-389432, EBI-366083;
CC       P09429; Q96B54: ZNF428; NbExp=3; IntAct=EBI-389432, EBI-9995882;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12231511,
CC       ECO:0000269|PubMed:17114460, ECO:0000269|PubMed:20819940,
CC       ECO:0000269|PubMed:22869893, ECO:0000269|PubMed:27362237,
CC       ECO:0000269|PubMed:29618516, ECO:0000269|Ref.71}. Chromosome
CC       {ECO:0000250|UniProtKB:P10103, ECO:0000250|UniProtKB:P63159,
CC       ECO:0000305}. Cytoplasm {ECO:0000269|PubMed:11154118,
CC       ECO:0000269|PubMed:12231511, ECO:0000269|PubMed:17114460,
CC       ECO:0000269|PubMed:20819940, ECO:0000269|PubMed:22869893,
CC       ECO:0000269|PubMed:29618516, ECO:0000269|Ref.71}. Secreted
CC       {ECO:0000250|UniProtKB:P63158, ECO:0000269|PubMed:12231511,
CC       ECO:0000269|PubMed:14532127, ECO:0000269|PubMed:15944249,
CC       ECO:0000269|PubMed:19811284, ECO:0000269|PubMed:22869893,
CC       ECO:0000269|Ref.71}. Cell membrane {ECO:0000250|UniProtKB:P63158,
CC       ECO:0000250|UniProtKB:P63159, ECO:0000269|PubMed:11154118}; Peripheral
CC       membrane protein {ECO:0000250|UniProtKB:P63158,
CC       ECO:0000250|UniProtKB:P63159, ECO:0000269|PubMed:11154118};
CC       Extracellular side {ECO:0000250|UniProtKB:P63158,
CC       ECO:0000250|UniProtKB:P63159, ECO:0000269|PubMed:11154118}. Endosome
CC       {ECO:0000250|UniProtKB:P63158}. Endoplasmic reticulum-Golgi
CC       intermediate compartment {ECO:0000250|UniProtKB:P63158}. Note=In basal
CC       state predominantly nuclear. Shuttles between the cytoplasm and the
CC       nucleus (PubMed:12231511, PubMed:17114460). Translocates from the
CC       nucleus to the cytoplasm upon autophagy stimulation (PubMed:20819940).
CC       Release from macrophages in the extracellular milieu requires the
CC       activation of NLRC4 or NLRP3 inflammasomes (By similarity). Passively
CC       released to the extracellular milieu from necrotic cells by diffusion,
CC       involving the fully reduced HGMB1 which subsequently gets oxidized
CC       (PubMed:19811284). Also released from apoptotic cells (PubMed:16855214,
CC       PubMed:18631454). Active secretion from a variety of immune and non-
CC       immune cells such as macrophages, monocytes, neutrophils, dendritic
CC       cells and natural killer cells in response to various stimuli such as
CC       LPS and cytokines involves a nonconventional secretory process via
CC       secretory lysosomes (PubMed:12231511, PubMed:14532127,
CC       PubMed:15944249). Secreted by plasma cells in response to LPS (By
CC       similarity). Found on the surface of activated platelets
CC       (PubMed:11154118). An increased chromatin association is observed when
CC       associated with the adenovirus protein pVII (PubMed:27362237).
CC       {ECO:0000250|UniProtKB:P63158, ECO:0000269|PubMed:11154118,
CC       ECO:0000269|PubMed:12231511, ECO:0000269|PubMed:14532127,
CC       ECO:0000269|PubMed:15944249, ECO:0000269|PubMed:16855214,
CC       ECO:0000269|PubMed:17114460, ECO:0000269|PubMed:18631454,
CC       ECO:0000269|PubMed:19811284, ECO:0000269|PubMed:20819940,
CC       ECO:0000269|PubMed:27362237, ECO:0000305|PubMed:20123072}.
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Expressed in platelets
CC       (PubMed:11154118). {ECO:0000269|PubMed:11154118}.
CC   -!- INDUCTION: (Microbial infection) Protein levels increase upon infection
CC       by human coronavirus SARS-CoV-2. {ECO:0000269|Ref.71}.
CC   -!- DOMAIN: HMG box 2 mediates proinflammatory cytokine-stimulating
CC       activity and binding to TLR4 (PubMed:12765338, PubMed:20547845).
CC       However, not involved in mediating immunogenic activity in the context
CC       of apoptosis-induced immune tolerance (PubMed:24474694).
CC       {ECO:0000269|PubMed:12765338, ECO:0000269|PubMed:20547845,
CC       ECO:0000269|PubMed:24474694}.
CC   -!- DOMAIN: The acidic C-terminal domain forms a flexible structure which
CC       can reversibly interact intramolecularily with the HMG boxes and
CC       modulate binding to DNA and other proteins (PubMed:23063560).
CC       {ECO:0000250|UniProtKB:P63159, ECO:0000305|PubMed:23063560}.
CC   -!- PTM: Phosphorylated at serine residues. Phosphorylation in both NLS
CC       regions is required for cytoplasmic translocation followed by secretion
CC       (PubMed:17114460). {ECO:0000269|PubMed:17114460}.
CC   -!- PTM: Acetylated on multiple sites upon stimulation with LPS
CC       (PubMed:22801494). Acetylation on lysine residues in the nuclear
CC       localization signals (NLS 1 and NLS 2) leads to cytoplasmic
CC       localization and subsequent secretion (By similarity). Acetylation on
CC       Lys-3 results in preferential binding to DNA ends and impairs DNA
CC       bending activity (By similarity). {ECO:0000250|UniProtKB:P10103,
CC       ECO:0000250|UniProtKB:P63159, ECO:0000269|PubMed:22801494}.
CC   -!- PTM: Reduction/oxidation of cysteine residues Cys-23, Cys-45 and Cys-
CC       106 and a possible intramolecular disulfide bond involving Cys-23 and
CC       Cys-45 give rise to different redox forms with specific functional
CC       activities in various cellular compartments: 1- fully reduced HMGB1
CC       (HMGB1C23hC45hC106h), 2- disulfide HMGB1 (HMGB1C23-C45C106h) and
CC       3- sulfonyl HMGB1 (HMGB1C23soC45soC106so).
CC       {ECO:0000269|PubMed:16962095, ECO:0000269|PubMed:19811284,
CC       ECO:0000269|PubMed:22869893, ECO:0000305|PubMed:24531895}.
CC   -!- PTM: Poly-ADP-ribosylated by PARP1 when secreted following stimulation
CC       with LPS (By similarity). {ECO:0000250|UniProtKB:P63158}.
CC   -!- PTM: In vitro cleavage by CASP1 is liberating a HMG box 1-containing
CC       peptide which may mediate immunogenic activity; the peptide antagonizes
CC       apoptosis-induced immune tolerance (PubMed:24474694). Can be
CC       proteolytically cleaved by a thrombin:thrombomodulin complex; reduces
CC       binding to heparin and proinflammatory activities (By similarity).
CC       {ECO:0000250|UniProtKB:P10103, ECO:0000269|PubMed:24474694}.
CC   -!- PTM: Forms covalent cross-links mediated by transglutaminase TGM2,
CC       between a glutamine and the epsilon-amino group of a lysine residue,
CC       forming homopolymers and heteropolymers. {ECO:0000269|PubMed:29618516}.
CC   -!- MISCELLANEOUS: Proposed to contribute to the pathogenesis of various
CC       chronic inflammatory and autoimmune diseases, and cancer. High serum
CC       levels are found in several inflammatory events including sepsis,
CC       rheumatoid arthritis, artherosclerosis chronic kidney disease, systemic
CC       lupus erythematosus (SLE). Seems to be implicated in other diseases
CC       characterized by cell death and damage, including diabetes and
CC       Alzheimer's disease. Its nucleosome-associated release during secondary
CC       necrosis may play a role in SLE (PubMed:19064698). During chemotherapy
CC       can mediate regrowth and metastasis of remaining cells in a AGER/RAGE-
CC       dependent manner (PubMed:23040637). Purified HMG box 1 acts as a
CC       specific antagonist to HGMB1 pro-inflammatory activities
CC       (PubMed:14695889). {ECO:0000269|PubMed:14695889,
CC       ECO:0000269|PubMed:23040637, ECO:0000305, ECO:0000305|PubMed:19064698,
CC       ECO:0000305|PubMed:24220159, ECO:0000305|PubMed:26078984}.
CC   -!- SIMILARITY: Belongs to the HMGB family. {ECO:0000305}.
CC   -!- CAUTION: Inconsistent experimental results may reflect the use of
CC       inconsistently defined redox forms. A recombinant fully reduced form
CC       has been used in a number of experiments. However, the redox states of
CC       HMGB1 administered in vivo, may interconvert among each other. Purified
CC       HMGB1 by itself has only weak pro-inflammatory activity. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/hmgb1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X12597; CAA31110.1; -; mRNA.
DR   EMBL; U51677; AAB08987.1; -; Genomic_DNA.
DR   EMBL; D63874; BAA09924.1; -; mRNA.
DR   EMBL; EF157968; ABM47301.1; -; Genomic_DNA.
DR   EMBL; AY377859; AAQ91389.1; -; mRNA.
DR   EMBL; AK291494; BAF84183.1; -; mRNA.
DR   EMBL; AK122825; BAG53745.1; -; mRNA.
DR   EMBL; CR749614; CAH18408.1; -; mRNA.
DR   EMBL; CR456863; CAG33144.1; -; mRNA.
DR   EMBL; BT006940; AAP35586.1; -; mRNA.
DR   EMBL; BT020159; AAV38961.1; -; mRNA.
DR   EMBL; EU012027; ABS29271.1; -; Genomic_DNA.
DR   EMBL; AL353648; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471075; EAX08457.1; -; Genomic_DNA.
DR   EMBL; BC003378; AAH03378.1; -; mRNA.
DR   EMBL; BC030981; AAH30981.1; -; mRNA.
DR   EMBL; BC066889; AAH66889.1; -; mRNA.
DR   EMBL; BC067732; AAH67732.1; -; mRNA.
DR   EMBL; BC141844; AAI41845.1; -; mRNA.
DR   CCDS; CCDS9335.1; -.
DR   PIR; S02826; S02826.
DR   RefSeq; NP_001300821.1; NM_001313892.1.
DR   RefSeq; NP_001300822.1; NM_001313893.1.
DR   RefSeq; NP_002119.1; NM_002128.5.
DR   PDB; 2LY4; NMR; -; A=2-84.
DR   PDB; 2RTU; NMR; -; A=1-84.
DR   PDB; 2YRQ; NMR; -; A=1-166.
DR   PDB; 6CG0; EM; 3.17 A; N=15-140.
DR   PDB; 6CIJ; EM; 3.90 A; N=1-163.
DR   PDB; 6CIK; X-ray; 3.15 A; N=1-163.
DR   PDB; 6CIL; X-ray; 4.15 A; N=1-163.
DR   PDB; 6CIM; X-ray; 3.60 A; N=1-163.
DR   PDB; 6OEM; EM; 3.60 A; H/N=15-155.
DR   PDB; 6OEN; EM; 4.30 A; H/N=1-163.
DR   PDB; 6OEO; EM; 3.69 A; N=1-163.
DR   PDBsum; 2LY4; -.
DR   PDBsum; 2RTU; -.
DR   PDBsum; 2YRQ; -.
DR   PDBsum; 6CG0; -.
DR   PDBsum; 6CIJ; -.
DR   PDBsum; 6CIK; -.
DR   PDBsum; 6CIL; -.
DR   PDBsum; 6CIM; -.
DR   PDBsum; 6OEM; -.
DR   PDBsum; 6OEN; -.
DR   PDBsum; 6OEO; -.
DR   BMRB; P09429; -.
DR   SMR; P09429; -.
DR   BioGRID; 109389; 313.
DR   CORUM; P09429; -.
DR   DIP; DIP-24195N; -.
DR   IntAct; P09429; 259.
DR   MINT; P09429; -.
DR   STRING; 9606.ENSP00000345347; -.
DR   BindingDB; P09429; -.
DR   ChEMBL; CHEMBL2311236; -.
DR   DrugBank; DB00608; Chloroquine.
DR   DrugBank; DB05869; Ethyl pyruvate.
DR   iPTMnet; P09429; -.
DR   MetOSite; P09429; -.
DR   PhosphoSitePlus; P09429; -.
DR   SwissPalm; P09429; -.
DR   BioMuta; HMGB1; -.
DR   DMDM; 123369; -.
DR   DOSAC-COBS-2DPAGE; P09429; -.
DR   EPD; P09429; -.
DR   jPOST; P09429; -.
DR   MassIVE; P09429; -.
DR   MaxQB; P09429; -.
DR   PaxDb; P09429; -.
DR   PeptideAtlas; P09429; -.
DR   PRIDE; P09429; -.
DR   ProteomicsDB; 52217; -.
DR   TopDownProteomics; P09429; -.
DR   ABCD; P09429; 23 sequenced antibodies.
DR   Antibodypedia; 3132; 1674 antibodies.
DR   DNASU; 3146; -.
DR   Ensembl; ENST00000339872; ENSP00000343040; ENSG00000189403.
DR   Ensembl; ENST00000341423; ENSP00000345347; ENSG00000189403.
DR   Ensembl; ENST00000399494; ENSP00000382417; ENSG00000189403.
DR   Ensembl; ENST00000405805; ENSP00000384678; ENSG00000189403.
DR   GeneID; 3146; -.
DR   KEGG; hsa:3146; -.
DR   UCSC; uc001usx.5; human.
DR   CTD; 3146; -.
DR   DisGeNET; 3146; -.
DR   GeneCards; HMGB1; -.
DR   HGNC; HGNC:4983; HMGB1.
DR   HPA; ENSG00000189403; Low tissue specificity.
DR   MIM; 163905; gene.
DR   neXtProt; NX_P09429; -.
DR   OpenTargets; ENSG00000189403; -.
DR   PharmGKB; PA188; -.
DR   VEuPathDB; HostDB:ENSG00000189403.14; -.
DR   eggNOG; KOG0381; Eukaryota.
DR   GeneTree; ENSGT00950000183120; -.
DR   InParanoid; P09429; -.
DR   OMA; YSQDKRP; -.
DR   OrthoDB; 1641977at2759; -.
DR   PhylomeDB; P09429; -.
DR   TreeFam; TF105371; -.
DR   PathwayCommons; P09429; -.
DR   Reactome; R-HSA-140342; Apoptosis induced DNA fragmentation.
DR   Reactome; R-HSA-445989; TAK1 activates NFkB by phosphorylation and activation of IKKs complex.
DR   Reactome; R-HSA-5686938; Regulation of TLR by endogenous ligand.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-879415; Advanced glycosylation endproduct receptor signaling.
DR   Reactome; R-HSA-933542; TRAF6 mediated NF-kB activation.
DR   SIGNOR; P09429; -.
DR   BioGRID-ORCS; 3146; 297 hits in 963 CRISPR screens.
DR   ChiTaRS; HMGB1; human.
DR   EvolutionaryTrace; P09429; -.
DR   GeneWiki; HMGB1; -.
DR   GenomeRNAi; 3146; -.
DR   Pharos; P09429; Tbio.
DR   PRO; PR:P09429; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; P09429; protein.
DR   Bgee; ENSG00000189403; Expressed in ventricular zone and 217 other tissues.
DR   ExpressionAtlas; P09429; baseline and differential.
DR   Genevisible; P09429; HS.
DR   GO; GO:0035868; C:alphav-beta3 integrin-HMGB1 complex; IDA:BHF-UCL.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0000793; C:condensed chromosome; IDA:UniProtKB.
DR   GO; GO:0005769; C:early endosome; IEA:Ensembl.
DR   GO; GO:0005793; C:endoplasmic reticulum-Golgi intermediate compartment; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0017053; C:transcription repressor complex; IDA:UniProtKB.
DR   GO; GO:0000405; F:bubble DNA binding; ISS:AgBase.
DR   GO; GO:0019958; F:C-X-C chemokine binding; IDA:UniProtKB.
DR   GO; GO:0010858; F:calcium-dependent protein kinase regulator activity; IEA:Ensembl.
DR   GO; GO:0042056; F:chemoattractant activity; ISS:UniProtKB.
DR   GO; GO:0005125; F:cytokine activity; ISS:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IDA:UniProtKB.
DR   GO; GO:0008301; F:DNA binding, bending; IMP:UniProtKB.
DR   GO; GO:0070182; F:DNA polymerase binding; IDA:UniProtKB.
DR   GO; GO:0003690; F:double-stranded DNA binding; ISS:UniProtKB.
DR   GO; GO:0003725; F:double-stranded RNA binding; IEA:Ensembl.
DR   GO; GO:0000400; F:four-way junction DNA binding; ISS:AgBase.
DR   GO; GO:0005178; F:integrin binding; IDA:BHF-UCL.
DR   GO; GO:0001530; F:lipopolysaccharide binding; IDA:UniProtKB.
DR   GO; GO:0016829; F:lyase activity; IDA:UniProtKB.
DR   GO; GO:0001786; F:phosphatidylserine binding; IDA:UniProtKB.
DR   GO; GO:0030295; F:protein kinase activator activity; IEA:Ensembl.
DR   GO; GO:0050786; F:RAGE receptor binding; ISS:UniProtKB.
DR   GO; GO:0070491; F:repressing transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0003697; F:single-stranded DNA binding; ISS:UniProtKB.
DR   GO; GO:0003727; F:single-stranded RNA binding; IEA:Ensembl.
DR   GO; GO:0097100; F:supercoiled DNA binding; ISS:AgBase.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0002218; P:activation of innate immune response; IDA:UniProtKB.
DR   GO; GO:0043277; P:apoptotic cell clearance; IDA:UniProtKB.
DR   GO; GO:0006309; P:apoptotic DNA fragmentation; TAS:Reactome.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0006284; P:base-excision repair; IEA:Ensembl.
DR   GO; GO:0098761; P:cellular response to interleukin-7; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; ISS:ARUK-UCL.
DR   GO; GO:0031497; P:chromatin assembly; IEA:Ensembl.
DR   GO; GO:0006342; P:chromatin silencing; IGI:UniProtKB.
DR   GO; GO:0002407; P:dendritic cell chemotaxis; ISS:UniProtKB.
DR   GO; GO:0032392; P:DNA geometric change; ISS:AgBase.
DR   GO; GO:0006310; P:DNA recombination; ISS:UniProtKB.
DR   GO; GO:0006265; P:DNA topological change; ISS:UniProtKB.
DR   GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; ISS:UniProtKB.
DR   GO; GO:0035767; P:endothelial cell chemotaxis; IEA:Ensembl.
DR   GO; GO:0001935; P:endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0001654; P:eye development; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; IDA:CACAO.
DR   GO; GO:0002437; P:inflammatory response to antigenic stimulus; IEP:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0002281; P:macrophage activation involved in immune response; IEA:Ensembl.
DR   GO; GO:0001773; P:myeloid dendritic cell activation; ISS:UniProtKB.
DR   GO; GO:2000426; P:negative regulation of apoptotic cell clearance; IDA:BHF-UCL.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; IDA:CACAO.
DR   GO; GO:0043371; P:negative regulation of CD4-positive, alpha-beta T cell differentiation; IDA:UniProtKB.
DR   GO; GO:0032689; P:negative regulation of interferon-gamma production; IDA:UniProtKB.
DR   GO; GO:0017055; P:negative regulation of RNA polymerase II transcription preinitiation complex assembly; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:UniProtKB.
DR   GO; GO:0031175; P:neuron projection development; ISS:UniProtKB.
DR   GO; GO:0097350; P:neutrophil clearance; IDA:UniProtKB.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0002270; P:plasmacytoid dendritic cell activation; IEA:Ensembl.
DR   GO; GO:0042104; P:positive regulation of activated T cell proliferation; IMP:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0010508; P:positive regulation of autophagy; IMP:UniProtKB.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IMP:BHF-UCL.
DR   GO; GO:2000343; P:positive regulation of chemokine (C-X-C motif) ligand 2 production; IDA:CACAO.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IDA:UniProtKB.
DR   GO; GO:2001200; P:positive regulation of dendritic cell differentiation; IMP:UniProtKB.
DR   GO; GO:0043388; P:positive regulation of DNA binding; IDA:UniProtKB.
DR   GO; GO:0051106; P:positive regulation of DNA ligation; ISS:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0045819; P:positive regulation of glycogen catabolic process; IEA:Ensembl.
DR   GO; GO:0032727; P:positive regulation of interferon-alpha production; IEA:Ensembl.
DR   GO; GO:0032728; P:positive regulation of interferon-beta production; IEA:Ensembl.
DR   GO; GO:0032731; P:positive regulation of interleukin-1 beta production; IEA:Ensembl.
DR   GO; GO:0032732; P:positive regulation of interleukin-1 production; IDA:UniProtKB.
DR   GO; GO:0032733; P:positive regulation of interleukin-10 production; IDA:UniProtKB.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; IMP:UniProtKB.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:UniProtKB.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; IDA:CACAO.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0032425; P:positive regulation of mismatch repair; IDA:UniProtKB.
DR   GO; GO:0071639; P:positive regulation of monocyte chemotactic protein-1 production; IEA:Ensembl.
DR   GO; GO:0090026; P:positive regulation of monocyte chemotaxis; IDA:UniProtKB.
DR   GO; GO:0045639; P:positive regulation of myeloid cell differentiation; IEA:Ensembl.
DR   GO; GO:1901224; P:positive regulation of NIK/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:1903672; P:positive regulation of sprouting angiogenesis; IEA:Ensembl.
DR   GO; GO:0034137; P:positive regulation of toll-like receptor 2 signaling pathway; IEA:Ensembl.
DR   GO; GO:0034145; P:positive regulation of toll-like receptor 4 signaling pathway; IEA:Ensembl.
DR   GO; GO:0034165; P:positive regulation of toll-like receptor 9 signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IDA:UniProtKB.
DR   GO; GO:1905564; P:positive regulation of vascular endothelial cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0090303; P:positive regulation of wound healing; IEA:Ensembl.
DR   GO; GO:2000819; P:regulation of nucleotide-excision repair; IEA:Ensembl.
DR   GO; GO:0032072; P:regulation of restriction endodeoxyribonuclease activity; IDA:UniProtKB.
DR   GO; GO:0002840; P:regulation of T cell mediated immune response to tumor cell; ISS:UniProtKB.
DR   GO; GO:0002643; P:regulation of tolerance induction; IDA:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0035711; P:T-helper 1 cell activation; IDA:UniProtKB.
DR   GO; GO:0045063; P:T-helper 1 cell differentiation; IMP:UniProtKB.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0033151; P:V(D)J recombination; IDA:UniProtKB.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   DisProt; DP01493; -.
DR   Gene3D; 1.10.30.10; -; 2.
DR   IDEAL; IID00297; -.
DR   InterPro; IPR009071; HMG_box_dom.
DR   InterPro; IPR036910; HMG_box_dom_sf.
DR   InterPro; IPR017967; HMG_boxA_CS.
DR   InterPro; IPR031076; HMGB1.
DR   PANTHER; PTHR48112:SF4; PTHR48112:SF4; 1.
DR   Pfam; PF00505; HMG_box; 1.
DR   Pfam; PF09011; HMG_box_2; 1.
DR   SMART; SM00398; HMG; 2.
DR   SUPFAM; SSF47095; SSF47095; 2.
DR   PROSITE; PS00353; HMG_BOX_1; 1.
DR   PROSITE; PS50118; HMG_BOX_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Adaptive immunity; ADP-ribosylation; Autophagy;
KW   Cell membrane; Chemotaxis; Chromosome; Cytoplasm;
KW   Direct protein sequencing; Disulfide bond; DNA damage; DNA recombination;
KW   DNA repair; DNA-binding; Endosome; Host-virus interaction; Immunity;
KW   Inflammatory response; Innate immunity; Isopeptide bond; Membrane; Nucleus;
KW   Oxidation; Phosphoprotein; Reference proteome; Repeat; Secreted.
FT   CHAIN           1..215
FT                   /note="High mobility group protein B1"
FT                   /id="PRO_0000048526"
FT   DNA_BIND        9..79
FT                   /note="HMG box 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00267"
FT   DNA_BIND        95..163
FT                   /note="HMG box 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00267"
FT   REGION          1..97
FT                   /note="Sufficient for interaction with HAVCR2"
FT                   /evidence="ECO:0000250|UniProtKB:P63158"
FT   REGION          1..10
FT                   /note="Heparin-binding"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   REGION          3..15
FT                   /note="LPS binding (delipidated)"
FT                   /evidence="ECO:0000269|PubMed:21660935"
FT   REGION          76..95
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          80..96
FT                   /note="LPS binding (Lipid A)"
FT                   /evidence="ECO:0000269|PubMed:21660935"
FT   REGION          89..108
FT                   /note="Cytokine-stimulating activity"
FT                   /evidence="ECO:0000269|PubMed:12765338"
FT   REGION          150..183
FT                   /note="Binding to AGER/RAGE"
FT                   /evidence="ECO:0000250|UniProtKB:P63159"
FT   REGION          161..215
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           27..43
FT                   /note="Nuclear localization signal (NLS) 1"
FT                   /evidence="ECO:0000250|UniProtKB:P63159"
FT   MOTIF           178..184
FT                   /note="Nuclear localization signal (NLS) 2"
FT                   /evidence="ECO:0000250|UniProtKB:P63159"
FT   COMPBIAS        76..94
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        161..187
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        188..215
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            10..11
FT                   /note="Cleavage; by thrombin:thrombomodulin"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   SITE            67..68
FT                   /note="Cleavage; by CASP1"
FT                   /evidence="ECO:0000269|PubMed:24474694"
FT   MOD_RES         3
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         7
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         8
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         12
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         23
FT                   /note="Cysteine sulfonic acid (-SO3H); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P63159"
FT   MOD_RES         28
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         29
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         30
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         35
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         43
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P63158"
FT   MOD_RES         45
FT                   /note="Cysteine sulfonic acid (-SO3H); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P63159"
FT   MOD_RES         90
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P63158"
FT   MOD_RES         100
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         106
FT                   /note="Cysteine sulfonic acid (-SO3H)"
FT                   /evidence="ECO:0000250|UniProtKB:P63159"
FT   MOD_RES         127
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         128
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         141
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P63158"
FT   MOD_RES         172
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         173
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         177
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         180
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         181
FT                   /note="ADP-ribosylserine"
FT                   /evidence="ECO:0000269|PubMed:28190768"
FT   MOD_RES         182
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         183
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         184
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         185
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   DISULFID        23..45
FT                   /note="In disulfide HMGB1; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P63159"
FT   CROSSLNK        28
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000269|PubMed:29618516"
FT   CROSSLNK        43
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000269|PubMed:29618516"
FT   CROSSLNK        44
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000269|PubMed:29618516"
FT   CROSSLNK        68
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000269|PubMed:29618516"
FT   CROSSLNK        180
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000269|PubMed:29618516"
FT   CROSSLNK        182
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000269|PubMed:29618516"
FT   CROSSLNK        183
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000269|PubMed:29618516"
FT   CROSSLNK        184
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000269|PubMed:29618516"
FT   VARIANT         11
FT                   /note="G -> R (in gastric-carcinoma cell line)"
FT                   /evidence="ECO:0000269|PubMed:9036861"
FT                   /id="VAR_046451"
FT   VARIANT         149
FT                   /note="A -> E (in gastric-carcinoma cell line)"
FT                   /evidence="ECO:0000269|PubMed:9036861"
FT                   /id="VAR_046452"
FT   VARIANT         156
FT                   /note="E -> Q"
FT                   /evidence="ECO:0000269|Ref.10"
FT                   /id="VAR_046453"
FT   VARIANT         190
FT                   /note="D -> G (in gastric-carcinoma cell line)"
FT                   /evidence="ECO:0000269|PubMed:9036861"
FT                   /id="VAR_046454"
FT   MUTAGEN         35
FT                   /note="S->A: Greatly reduces phosphorylation, nuclear
FT                   localization; when associated with A-39; A-42; A-46; A-53
FT                   and A-181."
FT                   /evidence="ECO:0000269|PubMed:17114460"
FT   MUTAGEN         35
FT                   /note="S->E: Cytoplasmic localization (phosphorylation
FT                   mimicking); when associated with E-39; E-42; E-46; E-53 and
FT                   E-181."
FT                   /evidence="ECO:0000269|PubMed:17114460"
FT   MUTAGEN         39
FT                   /note="S->A: Greatly reduces phosphorylation, nuclear
FT                   localization; when associated with A-35; A-42; A-46; A-53
FT                   and A-181."
FT                   /evidence="ECO:0000269|PubMed:17114460"
FT   MUTAGEN         39
FT                   /note="S->E: Cytoplasmic localization (phosphorylation
FT                   mimicking); when associated with E-35; E-42; E-46; E-53 and
FT                   E-181."
FT                   /evidence="ECO:0000269|PubMed:17114460"
FT   MUTAGEN         42
FT                   /note="S->A: Greatly reduces phosphorylation, nuclear
FT                   localization; when associated with A-35; A-39; A-46; A-53
FT                   and A-181."
FT                   /evidence="ECO:0000269|PubMed:17114460"
FT   MUTAGEN         42
FT                   /note="S->E: Cytoplasmic localization (phosphorylation
FT                   mimicking); when associated with E-35; E-39; E-46; E-53 and
FT                   E-181."
FT                   /evidence="ECO:0000269|PubMed:17114460"
FT   MUTAGEN         46
FT                   /note="S->A: Greatly reduces phosphorylation, nuclear
FT                   localization; when associated with A-35; A-39; A-42; A-53
FT                   and A-181."
FT                   /evidence="ECO:0000269|PubMed:17114460"
FT   MUTAGEN         46
FT                   /note="S->E: Cytoplasmic localization (phosphorylation
FT                   mimicking); when associated with E-35; E-39; E-42; E-53 and
FT                   E-181."
FT                   /evidence="ECO:0000269|PubMed:17114460"
FT   MUTAGEN         53
FT                   /note="S->A: Greatly reduces phosphorylation, nuclear
FT                   localization; when associated with A-35; A-39; A-42; A-46
FT                   and A-181."
FT                   /evidence="ECO:0000269|PubMed:17114460"
FT   MUTAGEN         53
FT                   /note="S->E: Cytoplasmic localization (phosphorylation
FT                   mimicking); when associated with E-35; E-39; E-42; E-46 and
FT                   E-181."
FT                   /evidence="ECO:0000269|PubMed:17114460"
FT   MUTAGEN         67
FT                   /note="D->A: Abolishes cleavage by CASP1 and impairs
FT                   ability to antagonize apoptosis-induced immune tolerance."
FT                   /evidence="ECO:0000269|PubMed:24474694"
FT   MUTAGEN         106
FT                   /note="C->S: Inhibits oxidation-dependent inactivation of
FT                   immunostimmulatory activity in apoptotic cells."
FT                   /evidence="ECO:0000269|PubMed:18631454"
FT   MUTAGEN         181
FT                   /note="S->A: Greatly reduces phosphorylation, nuclear
FT                   localization; when associated with A-35; A-39; A-42; A-46
FT                   and A-53."
FT                   /evidence="ECO:0000269|PubMed:17114460"
FT   MUTAGEN         181
FT                   /note="S->E: Cytoplasmic localization (phosphorylation
FT                   mimicking); when associated with E-35; E-39; E-42; E-46 and
FT                   E-53."
FT                   /evidence="ECO:0000269|PubMed:17114460"
FT   CONFLICT        143
FT                   /note="P -> H (in Ref. 13; AAI41845)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        215
FT                   /note="E -> D (in Ref. 8; CAG33144)"
FT                   /evidence="ECO:0000305"
FT   STRAND          1..3
FT                   /evidence="ECO:0007829|PDB:2YRQ"
FT   STRAND          6..8
FT                   /evidence="ECO:0007829|PDB:2YRQ"
FT   HELIX           20..30
FT                   /evidence="ECO:0007829|PDB:6CIK"
FT   STRAND          31..33
FT                   /evidence="ECO:0007829|PDB:6CIK"
FT   HELIX           38..47
FT                   /evidence="ECO:0007829|PDB:6CIK"
FT   HELIX           54..76
FT                   /evidence="ECO:0007829|PDB:2LY4"
FT   STRAND          92..94
FT                   /evidence="ECO:0007829|PDB:2YRQ"
FT   HELIX           101..116
FT                   /evidence="ECO:0007829|PDB:6CIK"
FT   STRAND          118..120
FT                   /evidence="ECO:0007829|PDB:2YRQ"
FT   HELIX           122..135
FT                   /evidence="ECO:0007829|PDB:6CIK"
FT   HELIX           138..140
FT                   /evidence="ECO:0007829|PDB:2YRQ"
FT   HELIX           142..157
FT                   /evidence="ECO:0007829|PDB:6CIK"
SQ   SEQUENCE   215 AA;  24894 MW;  8A868CF277D417B5 CRC64;
     MGKGDPKKPR GKMSSYAFFV QTCREEHKKK HPDASVNFSE FSKKCSERWK TMSAKEKGKF
     EDMAKADKAR YEREMKTYIP PKGETKKKFK DPNAPKRPPS AFFLFCSEYR PKIKGEHPGL
     SIGDVAKKLG EMWNNTAADD KQPYEKKAAK LKEKYEKDIA AYRAKGKPDA AKKGVVKAEK
     SKKKKEEEED EEDEEDEEEE EDEEDEDEEE DDDDE
//
